

### **DISCLAIMER**

This presentation is incomplete without reference to, and should be viewed solely in conjunction with the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which includes certain information drawn from public sources does not purport to be comprehensive and has not been independently verified. It has been prepared and issued by and is the sole responsibility of the Company.


No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness. No representation or warranty, express or implied, is given by the Company, any of its subsidiaries or any of its advisors, directors, officers, employees or agents, as to the accuracy, reliability or completeness of the information or opinions contained in this presentation or in any revision of the presentation or of any other written or oral information made or to be made available to any information or opinions (which should not be relied upon) and no responsibility is accepted for any errors, misstatements in or omissions from this presentation or for any loss howsoever arising, directly or indirectly, from any use of this presentation or its contents. The information and opinions contained in this presentation are provided as at the date of this presentation and are subject to change without notice.

In particular, this presentation may contain certain forward looking statements that are subject to the usual risk factors. Whilst the Company believes the expectations reflected herein to be reasonable in light of the information available to them at this time, the actual outcome may be materially different owing to factors beyond the Company's control or with in the Company's control where, for example the Company decides on a change of strategy. Accordingly no reliance may be placed on the figures or other indications contained in any such potential forward-looking statements. No representation or warranty of any kind is made with respect to the accuracy or completeness of the financial projections or other forward looking statements, any assumptions

underlying them, the future operations or the amount of any future income or loss.

The content of this presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA"). This presentation does not constitute or form part of any offer or invitation to see, or any solicitation of any offer to purchase or subscribe for or otherwise acquire, any securities in the Company in any jurisdiction or any other body corporation or an invitation or an inducement to engage in investment activity under section 21 of FSMA, nor shall it or any part of it form the basis of or be relied on in connection with any contract therefore. This presentation does not constitute an invitation to effect any transaction with the Company or to make use of any services provided by the Company. Reliance on the information contained in this presentation for the purposes of engaging in any investment activity may expose the investor to a significant risk of losing all of the property or assets invested. Any person who is in any doubt about the investment in business to which this presentation relates should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

By attending the presentation, or reading or accepting this document you agree to be bound by the foregoing limitations.



### **PRESENTING**



**SEAN SMITH**CHIEF EXECUTIVE OFFICER

Over 25 years experience in the speciality chemicals and industrial biotechnology industries

- 5+ years as CEO
- Extensive industry experience in IP-based businesses
- Senior roles previously at Ciba (now BASF) and Honeywell



### **ABOUT US**


Eden is the only UK quoted (AIM: EDEN) company

focused on **biopesticides for sustainable agriculture** 

Intellectual property and expertise in plant-derived sustainable chemistry and delivery technologies

- Proven products
- Multiple regulatory clearances
- Strategic partnerships
- Two products commercially available





# INDUSTRY APPLICATIONS

We work globally through multi-national and local partnerships to develop and launch solutions for challenges facing **three key industries**.



### **CROP PROTECTION**

Foliar disease & insect control
Open field & greenhouses
Soil pests
Post harvest shelf-life extension
Seed treatments

\$58 billion



### ANIMAL HEALTH

Shampoos/Conditioners
Skin disease control
OTIC flush
Flea & tick control

\$33 billion



### **CONSUMER PRODUCTS**

Head-lice treatment
Deodorants
Odour neutralisers
Fragrances

\$50+ billion











SIGNIFICANT MARKET POTENTIAL

## A GROWING GLOBAL MARKET FOR SUSTAINABLE PRODUCTS

- The global biopesticides market is projected to be worth more than
   \$10 billion by 2025
- The biopesticides market is growing at a CAGR of approximately
   15% per annum
- Increasing time and cost of bringing new agrochemical products to market: 10 to 12 years and around \$300 million

Conventional crop protection products formulated with Sustaine and Eden's active ingredients can help address many of these issues:

**Consumer concerns over food safety** 

**Increasingly challenging** regulatory requirements

**Farmers seeking effective alternatives** 











### SIGNIFICANT MARKET OPPORTUNITIES

Researchers: Pesticides influence ground-nesting bee development and longevity

by Bioengineer March 13 at 8:20 PM



#### BUSINESS INSIDER

Kale is now one of the most pesticide-contaminated vegetables, and the dangers go beyond eating salad

**Aria Bendix** Mar 25, 2019 | 4:18 PM ET

EPA Must Ban Dangerous Insecticide: What is It?

Chlorpyrifos has been linked to low IQ and developmental problems in children, but it has been in the environment for a very long time.

BY LORI CUTHBERT
PUBLISHED AUGUST 10, 2018

Damian Carrington
Environment editor

EU bans UK's most-used pesticide over health and environment fears

Officials say chlorothalonil poses high risk to wildlife and may potentially harm humans

SCIENTIFIC AMERICAN.

As Pesticide Turns Up in More Places, Safety Concerns Mount

Jim Daley | Apr 30, 2019 | 11:45 AM

### **OUR TECHNOLOGY**


WE HAVE DEVELOPED A NATURAL FORMULATION TECHNOLOGY,

SUSTAINETM

Particles are derived from **natural yeast cells** originally developed for human health applications

Sustaine encapsulates active ingredients and provides for the **sustained release** of these ingredients enabling their **safe, more efficient use** 

Cost effective, **useful for a wide range of active ingredients**, **plastic-free**, high capacity, robust, **sustainable** 



### **OUR PRODUCT FOCUS**


Our focus is developing products based on sustainable chemistries to protect high-value crops from pests and disease, with equal or better performance when compared with conventional pesticides.

### Our products:

- are exempt from pesticide residue limits
- are allowed in EU organic agriculture
- can be used up to the point of harvest
- are equally effective vs. conventional chemistry


....giving growers reduced risk, increased flexibility and security.





### **RESULTS**

- Mevalone is a proven product
- A reliable alternative to conventional control
- Phased release for prolonged effects
- Easy to use and apply
- Improved stability and shelf life compared to other biological options






## **QUALITY**

- Superior crop quality
- Enhanced marketability
- Improved ROI















Market sizes (ex-Eden)*										
	Mites	Whitefly	Thrips	Aphids	Total					
US	€159m	€5m	€59m	€107m	€330m					
Europe (incl. Turkey)	€147m	€97m	€85m	€192m	€521m					

<sup>\*</sup> Company estimates

- Eden is developing a product for use against key insect pests including whitefly, aphids, thrips and mites
- There is an urgent need for an effective alternative to conventional insecticides due to strong consumer and regulatory pressure (persistence, bio-accumulation, toxicity and susceptibility to resistance)

### **COMMERCIALISATION ROADMAP**

Market size

€0.6bn

€0.5bn

€1.9bn

>€45bn



Mevalone



Cedroz



Insecticide



Sustaine

Regulatory process

Product sales



### PRODUCT COMMERCIALISATION

WE NOW HAVE COMMERCIAL PARTNERS IN PLACE ACROSS

SIX CONTINENTS.

**Product sales have commenced in key** markets where we have authorisation to market and sell our first product, Mevalone.

Eden Research has **new product** registration applications in-process in multiple new countries with initial approval received for its second product in 2019.





**Strong intellectual** property portfolio



A demonstrated platform for future product development



**Regulatory approvals** in a growing list of key markets



**Numerous commercial** partnerships



**Active engagement** with new partners



**Growing market share** 



**Investment in research** and development



# COMPETITOR ANALYSIS

Company	Approx. size (mkt cap)	High efficacy	Low PHI	No resistance	Plastic free	Residue limit exempt	Allowable for organic
EDEN THE NATURAL SOLUTION	£15m	<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>
syngenta*	\$41B	<b>√</b>	Х	X	Х	Х	X
* BASF We create chemistry	\$62B	<b>√</b>	✓	Χ	Х	Х	X
Crop Science*	\$71B	<b>√</b>	✓	Χ	X	Х	X
Marrone' Bio Innovations *	\$140M	X	<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>	<b>√</b>

### **CORTEVA AGREEMENT**

- The world's leading Agriscience pure play
- Exclusive evaluation agreement signed with Eden on 8 January 2020
- Regulatory change has led to the withdrawal of key seed products for one of Corteva's key product lines in the EU
- Initial trials by Corteva have shown strong results using Eden's products and formulation technology
- Eden's formulation technology is stable, environmentally friendly and complies with emerging EU regulations concerning polymers
- Further trials will be undertaken under a one-year evaluation agreement
- If successful, Corteva and Eden will look to sign a distribution agreement for the EU, Russia, Ukraine and Turkey giving Eden the opportunity to capture a significant share of this market
- If successful, there is the opportunity to generate up to c. €40m of revenue for Eden from European geographies alone (current market)



Corteva Agriscience combines the crop protection chemical and seed businesses of Dow Chemical and DuPont, which merged in 2017.

**GLOBAL RANKING: #01** 

Press Release • 1/8/2020

# Corteva Agriscience to evaluate use of plastic-free capsules under Eden Research plc agreement

The Sustaine  $^{\text{IM}}$  biological yeast-based capsules help reduce use of microplastics

**GENEVA**, **Switzerland**, **Jan.** 8, 2020 – A new agreement between Corteva Agriscience and Eden Research plc will support farmers as they strive to meet consumer demands for more sustainable agriculture. Eden Research plc is an AIM listed company that develops and supplies sustainable solutions for crop protection, animal health and consumer products.

The exclusive evaluation agreement allows NYSE-listed pure-play agriculture company Corteva Agriscience to further evaluate Eden's Sustaine™ encapsulation technology and several formulations in biological seed treatment applications in certain major territories.

Market Cap

£21.3bn

Revenue

£19.7bn





### **STRATEGY**

### **COMMERCIAL GROWTH**

- Regulatory clearance in new countries, crops and diseases
- Accelerate Sustaine business development
- Partnerships for Mevalone in new territories
- Pursue collaboration with majors

## RESEARCH, DEVELOPMENT AND OPERATIONS

- Supply chain optimisation
- Expansion of screening and field trials
- Accelerate commercialisation of Sustaine for conventional actives

#### **BUSINESS LINE DIVERSIFICATION**

- Ongoing work with Bayer Animal Health to launch four new products
- Consumer product launches
- Pursuing opportunities in the seed treatments market
- Expand crops and diseases treated
- Geographic diversification (seasonal and climatic variation)

## STRENGTHENING AND GROWING THE TEAM

 Commercial, product management and technical roles











### INVESTMENT SUMMARY

- COMMERCIALISATION

  Eden to commercialise multiple products and accelerate growth
- 2 TECHNOLOGY EXPLOITATION
  Ability to exploit Eden's core technologies beyond biopesticides and crop protection
- FOCUS ON BIOLOGICAL SOLUTIONS

  Eden is the only UK quoted company with a focus on biopesticides for the crop protection market
- 4 REGULATORY DRIVERS FOR SUSTAINABLE SOLUTIONS
  Regulatory developments in accelerating Eden's product portfolio through to commercialisation

5 INCREASE NUMBER OF COMMERCIAL PARTNERS

Opportunity to increase the number of commercial partners and diversify product range

- PATENT PORTFOLIO110 patents enable strong technological defensibility
- **REVENUE GROWTH**Ability for Eden to generate significant additional revenue in the medium term
- CORTEVA AGREEMENT
  Opportunity up to €40 million of revenue in a limited number of geographies, with significant upside potential



## COMPETITIVE ADVANTAGE

Our products harness the biocidal activity of naturally occurring molecules produced by plants as part of their defence systems. **These active ingredients are known as terpenes**.

Our biopesticides, formulated with Sustaine, add value compared to conventional pesticides by:

**Enabling sustained delivery,** increasing residual efficacy and reducing use rates

**Tackling resistance build-up** 

**Protecting plants** from potentially damaging chemicals

Allowing solvent-free, stable formulations with high loadings of active ingredients

Naturally binding to plant and animal surfaces improving efficacy and retention

Polymer-free formulation technology

Exemption from maximum residue levels

Low or no pre-harvest intervals giving growers increased flexibility, security and control

### **ROBUST EFFICACY**

Mevalone has demonstrated comparable control to that of established products both in registration trials and commercial applications.


### **Critically, our products are:**

Comparable to conventional fungicides

Complementary to existing application programmes


A valuable part of Integrated Pest Management





## **QUALITY FACTORS**


- In depth testing of crop quality in grapes
- Results demonstrate that Mevalone performs equally to conventional fungicide
- No negative effects on grape fermentation





### **POWDERY MILDEW**

- Efficacy against Powdery Mildew
- Mevalone outperforms other plant based options developed specifically for Powdery Mildew
- Superior performance to biological alternatives






### **CROP PROTECTION MARKET**

The dominant molluscicide approved for use in the EU is **metaldehyde**. The UK banned metaldehyde in 2018. **AHDB estimates that a lack of slug control products will cost UK agriculture £100 million per year!** 

The re-registration of **copper-based products** as fungicides was approved in the EU but a **33% reduction in use limit was imposed.** 

New EU rules have prohibited any substance identified as an **Endocrine Disruptor** from being used in plant protection products. **The new rules will have an impact upon** the availability of insecticides and fungicides.













## **UNIQUE TECHNOLOGY**

- Ownership of the patents behind the Sustaine encapsulation technology
- Significant investment in patent protection and the registration of new actives
- Proven efficacy with strong commercial validation by farmers and our partners
- Scope to exploit the core technologies beyond existing markets and products

Eden's products serve as sustainable alternatives to conventional chemicals without limitations such as residue limits, pest resistance, pre-harvest intervals, long field re-entry periods or increasing restrictions on use.

Residue-free crops command a higher value and have a significant commercial advantage in the valuable export markets.











### RECENT HIGHLIGHTS



Successful positioning of Mevalone as an early-season treatment contributing to product sales growth of 112% in 2018 Regulatory trials supporting label extensions on crops and the authorisation in Central Europe for the treatment of botrytis on grapes

Robust results and emergency approval in France supporting the first use of Mevalone for post harvest applications

Our second product has received initial clearance in the EU and emergency approval in Italy in 2019

Finalist in two categories in the 2019 Agribusiness Intelligence Crop Science Awards: Best Biological Product and Best Formulation Innovation



### **MEET THE BOARD**



**SEAN SMITH**CHIEF EXECUTIVE OFFICER
Over 25 years experience in the speciality chemicals and industrial biotechnology industries



LYKELE VAN DER BROEK
NON-EXECUTIVE CHAIRMAN
Formerly Board member of Bayer Crop Science and
President of Bayer Animal Health, both divisions of Bayer AG



ALEX ABREY
CHIEF FINANCIAL OFFICER
Experienced Financial Director to a diverse range of businesses including financial and management consultancy



ROB CRIDLAND

NON-EXECUTIVE DIRECTOR

Until recently, Rob served as Chief Financial Officer of Itaconix plc, having joined from Renovo Group plc where he was Executive Director of Finance and Business Development

